Traders assign a strong 92.5% implied probability to no new COVID variant of concern before 2027 because circulating SARS-CoV-2 lineages remain dominated by Omicron subvariants such as XFG.1.1, with no mutations triggering WHO or CDC reclassification in recent months. Low emergency department visits, stable wastewater surveillance, and de-escalation of older lineages reflect limited impact on transmissibility, severity, or vaccine effectiveness. Population immunity from prior infections and updated shots continues to constrain major shifts, while monitoring focuses on variants under observation rather than urgent new designations. Resolution hinges on official CDC labeling through December 2026, and current trends show no near-term catalysts likely to alter that outlook.